You are reading 1 of 2 free-access articles allowed for 30 days
GreenLight commissioned research is now currently underway in a number of universities throughout Ireland and the UK, including: University College Dublin (UCD), the RCSI and Ulster University. UCD will be investigating cancer and in a joint study between UCD and Imperial College London, there will be a study on addiction. A study by the RCSI will focus on epilepsy, while Ulster University will investigate arthritis.
Queen’s University Belfast, University College Cork (UCC) and NUI Galway will commence research in early 2017.
Commenting on the company’s current studies in Ireland, GreenLight Medicines founder and CEO Dr James Linden says: “There’s mounting evidence that cannabinoids are an effective form of treatment for many illnesses, including multiple sclerosis (MS), glaucoma, arthritis, epilepsy, and cancer. GreenLight’s focus is on conducting research that will be the catalyst in bringing these life-changing medicines to fruition, that have the potential to help thousands of people manage their conditions.
“We’ve spent the last 24 months developing research programmes with many universities in Ireland… and we’re thrilled that the first tranche of research projects are now live.”
Founded in 2015, the team behind the research and development company is comprised of internationally-recognised researchers and scientists. Former Chairman of the UK’s Advisory Council on the Misuse of Drugs (ACMD), neuroscientist and psychiatrist, Prof David Nutt of Imperial College London, has just been appointed as GreenLight’s Chief Medical Officer. Other internationally-recognised experts on the team include cancer researcher Prof William Gallagher from UCD, cannabinoids researcher Prof David Finn from NUI Galway, biochemist Prof Tom Cotter from UCC, and Prof David Henshall, Chairman of Neuroscience Ireland, who leads a team of over 20 researchers in the study of epilepsy.